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Blood vessels supplying tumors are often dysfunctional and generally heterogeneous. The 38 
mechanisms underlying this heterogeneity remain poorly understood. Here, using 39 
multicolor lineage tracing, in vivo time-lapse imaging and single cell RNA sequencing in 40 
a mouse glioma model, we identify tumour-specific blood endothelial cells that originate 41 
from cells expressing the receptor for colony stimulating factor 1, Csf1r, a cytokine which 42 
controls macrophage biology. These Csf1r lineage endothelial cells (CLECs) form up to 43 
10% of the tumour vasculature and express, besides classical blood endothelial cell 44 
markers, a gene signature that is distinct from brain endothelium but shares similarities 45 
with lymphatic endothelial cell populations. in silico analysis of pan-cancer single cell 46 
RNAseq datasets highlights the presence of a comparable subpopulation in the 47 
endothelium of a wide spectrum of human tumours. We show that CLECs actively 48 
contribute to sprouting and remodeling of tumour blood vessels and that selective 49 
depletion of CLECs reduces vascular branching and tumour growth. Our findings indicate 50 
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that a non-tumour resident Csf1r-positive population is recruited to tumours, 51 
differentiates into blood endothelial cells to contribute to vascularization and, thereby, 52 




Endothelial cells form a single cell layer lining the inner walls of blood vessels and play 57 
critical roles in organ homeostasis and disease progression. Once formed, following 58 
embryonic and early post-natal development, blood vessels retain a high level of 59 
adaptability to meet changing metabolic or hemodynamic requirements or enable further 60 
tissue growth including in tumours. How local vascular networks respond to these 61 
adaptive challenges, rapidly expand, remodel and reestablish homeostasis remains a 62 
timely research topic, with many open questions still unresolved. In particular in 63 
pathologies, knowledge of the precise nature and origin of new vessel formation, 64 
endothelial activation and differentiation steps, and of the mechanisms driving vessel 65 
dysmorphia, or preventing effective revascularization in ischemic diabetic complication 66 
is critical for new therapeutic approaches. New blood vessel formation in the adult was 67 
long believed to arise exclusively by sprouting and proliferation of endothelial cells from 68 
local blood vessels without any de novo differentiation from progenitor cells. However, 69 
Asahara and coworkers isolated mononuclear cells from human peripheral blood and 70 
identified circulating endothelial progenitor cells (EPCs) 1. These cells were shown to 71 
derive from the bone marrow and contribute to endothelial cells in blood vessels in 72 
hindlimb ischemia and tumour xenograft mouse model 2,3. By fluorescent in situ 73 
hybridization with sex chromosome-specific probes in patients with cancer after bone 74 
marrow transplantation, Peters and coworkers demonstrated that bone marrow-derived 75 
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stem cells contribute to endothelial cells in human tumour endothelium 4. The resulting 76 
concept of vasculogenesis in the adult raised the prospect of novel therapeutic approaches 77 
for ischemic vascular disease and for targeting tumour angiogenesis 5,6. Interestingly, 78 
EPCs also contributed to newly forming lymphatic vessels 7,8. A vast number of 79 
publications since have supported or challenged these initial discoveries, and the 80 
occurrence, origin and significance of EPCs continues to be a matter of debate 9-12. 81 
Whereas EPCs and other circulating progenitor cells were long thought to origin from the 82 
bone marrow, recent studies challenged this idea and suggested the existence of a 83 
different yet unknown vascular niche for endothelial progenitor cells that can contribute 84 
to blood vessel formation13. 85 
 86 
RESULTS  87 
A Csf1r cell lineage contributes to blood vascular endothelial cells during glioma 88 
growth in mice. 89 
In order to study dynamic macrophage recruitment and blood vessel patterning in vivo 90 
during glioma growth, we adapted a surgical cranial window model for two-photon 91 
microscopy allowing repeated visualization of the same animal over time. We generated 92 
spheroids of syngeneic C57BL/6 mouse glioma cells (CT2A or GL261) 14,15 modified to 93 
stably express blue fluorescent protein (BFP), and injected them into the mouse cortex, 94 
followed by implantation of a glass coverslip 16. By crossing transgenic Csf1r (Colony 95 
stimulating factor 1 receptor)  specific tamoxifen-inducible Cre driver mice 17 with the 96 
mTmG Cre reporter mouse line 18, we induced membrane-targeted GFP expression in 97 
Csf1r-expressing cells and used this stable lineage trace to follow the cell population over 98 
time (Fig. 1a, b). As expected, the vast majority of tumour associated macrophages were 99 
labelled by GFP in line with their Csf1r-dependent recruitment and expansion19. 100 
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 5 
Unexpectedly, however, through the combination of longitudinal live two-photon 101 
imaging and lineage tracing, we discovered GFP-positive cells contributing to the tumour 102 
vasculature during glioma growth (Fig. 1c). These Csf1r lineage endothelial cells 103 
(CLECs) frequently emerged at tip cell positions of the growing vasculature, heading 104 
blood vessel sprouts in the mouse glioma (Fig. 1d, Supplementary Movie1). Additionally, 105 
CLECs were found bridging adjacent capillaries during anastomosis (Fig. 1e). 106 
Fluorescent dextran injection confirmed that CLECs contributed to - and were 107 
incorporated in the endothelial lining of - functionally perfused blood vessels including 108 
lumenized sprouts headed by endothelial tip cells (Fig. 1f). Counterstaining on fixed 109 
samples identified that all cells forming blood vessels including the lineage-traced CLECs 110 
expressed typical endothelial markers (CDH5, CD31) and lacked macrophage and 111 
myeloid cell markers (F4/80, CD45) (Fig. 1g, h, Extended Data Fig. 1). BFP was not 112 
expressed in CLECs, demonstrating that they were not derived from glioma cells (Fig. 113 
1g).  114 
To gain more insight into the nature and significance of CLECs, we isolated and 115 
quantified the cell population in the mouse glioma model. By 4 weeks of tumour 116 
development (close to the specified humane endpoint of 5 weeks) up to 10% of the tumour 117 
vasculature was comprised of cells carrying the Csfr1 lineage trace. Similar frequencies 118 
were found in tumours derived from either of the mouse glioma cell lines, CT2A (Fig. 2a, 119 
b), or GL261 (Fig. 2c). Polyclonal antibody staining indicated that Csf1r may also be 120 
expressed in some brain capillary endothelial cells 20,21. Recent single cell sequencing of 121 
adult mouse brain endothelial cells however did not confirm this notion22, suggesting that 122 
CLECs are unlikely to originate from brain endothelium. Indeed, tamoxifen mediated 123 
activation of our transgenic Csfr1 lineage trace did not label brain endothelial cells in 124 
mice lacking tumours, sham operated as well as in the healthy brain parenchyma 125 
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surrounding implanted tumours (Fig. 2d, e, f). Csf1r is important for the embryonic 126 
development of microglia and its expression is also detected in adult microglia by single 127 
cell RNA sequencing. Surprisingly however, Csf1r-Mer-iCre-Mer mediated 128 
recombination of the Cre-Reporter expression was also not observed in microglia of the 129 
healthy adult mouse brain. Irrespective of this apparent discrepancy between reported 130 
microglial Csf1r expression and the lack of Csf1r- Mer-iCre-Mer mediated recombination 131 
in microglia, these data also exclude microglia as a potential source of CLECs. 132 
Furthermore, we observed CLECs also in tumours originating from B16F1 melanoma 133 
cells implanted under the skin; thus, this Csfr1-lineage endothelial cell contribution not 134 
only occurs in brain tumours with microglia in their environment, but also in other tumour 135 
types and locations (Fig. 2g, h). Notably, we also found Csf1r-lineage lymphatic 136 
endothelial cells in B16F1 skin melanomas indicating that CLECs can contribute to both 137 
blood and lymphatic vessels (Extended Data Fig. 2). 138 
CLECs do not originate from hematopoietic niche in bone-marrow or spleen. 139 
Given the abundant labelling of macrophages and the important role of Csf1r in the 140 
recruitment of bone-marrow derived monocytes and differentiated macrophages, we 141 
asked whether CLECs are also derived from the bone-marrow. To test this possibility, we 142 
generated bone marrow chimeras. Flow cytometric analysis confirmed 97.3 ± 1.6 % 143 
reconstitution of wild-type recipient bone marrow by transplanted Csf1r-Mer2.CremTmG 144 
bone marrow after 8 weeks post transplantation (Extended Data Fig. 3). Analysis of 145 
glioma blood vessels in these bone marrow chimeras (BMCsf1r-Mer2.Cre-mTmG) failed to 146 
identify bone marrow derived CLECs, although the numbers of tumour macrophage were 147 
similar to controls (Fig. 3a). Conversely, chimeras of wild-type donor bone marrow 148 
transplanted into Csf1r-Mer2.CremTmG recipients (Csf1r-Mer2.CremTmG::BMWT), 149 
displayed similar CLECs numbers in glioma vessels as observed earlier in non-chimeric 150 
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Csf1r-Mer2.CremTmG mice (Fig. 3b). These results were confirmed by intravital imaging 151 
in the glioma of Csf1r-Mer2.CremTmG::BMWT (Fig. 3c, Supplemental Movie 2). Thus, the 152 
bone marrow chimera and lineage tracing experiments strongly suggest that CLECs do 153 
not originate from bone marrow-derived cells, nor do they represent previously suggested 154 
transdifferentiation events from bone marrow-derived macrophages. Surgical removal of 155 
the spleen also did not affect CLECs numbers, further ruling out spleen-derived 156 
macrophages as source of CLECs (Extended Data Fig. 4).    157 
CLECs regulate vascular patterning and support glioma growth. 158 
 In late-stage gliomas, CLECs preferentially localized to the peripheral tumor area, 159 
correlating with the zone of most active angiogenesis (Extended Data Fig. 5). Real-time 160 
intravital imaging of mouse gliomas also revealed that CLECs incorporation into vessels 161 
is very dynamic. This implied that CLECs might have unique and potentially transient 162 
functions during tumour vessel formation. To gain a better understanding of CLECs 163 
behaviour during tumour growth, we developed dual-recombination combinatorial 164 
genetics as a tool for CLECs tracing 23,24. To achieve selective recombination in CLECs, 165 
we used the Cdh5 endothelial driver for expression of the Dre recombinase, and the same 166 
transgenic mouse line as above expressing the tamoxifen inducible form of the Cre 167 
recombinase under control of the Csf1r transgene. The combined action of these distinct 168 
recombinases, Dre and Cre, allowed for deletion of two stop cassettes flanked by RoxP 169 
and LoxP sites, respectively, located upstream of a tdTomato expression cassette (Fig. 170 
4a). Using this strategy, we could selectively trace tdTomato-positive CLECs in mouse 171 
gliomas following tamoxifen exposure (Fig. 4b). Note that the appearance of labelled 172 
CLECs and blood vessel labelling differs from the images of the mTmG line, as the dual 173 
Dre/Cre tdTomato reporter used lacks a general label of unrecombined cells. Fluorescent 174 
dextran injection instead was used to label vascular lumen, highlighting dtTomato 175 
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positive CLECs that line the vessel lumen. As expected, counterstaining on fixed samples 176 
demonstrated that CLECs express the prototypical endothelial marker, ERG (ETS-related 177 
gene) (Fig. 4c). In order to assess whether CLECs contribute functionally to tumour 178 
growth and vascular patterning in glioma, we used the same dual recombination strategy 179 
to selectively ablate CLECs (Fig. 4d). In this model, CLECs expressed both GFP as well 180 
as the diphtheria toxin receptor after tamoxifen induction enabling depletion of GFP-181 
positive CLECs by administration of diphtheria toxin (Fig. 4e, h). Strikingly, CLECs 182 
ablation significantly decreased glioma growth (Fig. 4g, i). CLECs ablation also 183 
decreased the vascular network length and the number of bifurcations in tumour vessels 184 
(Fig. 4j, k, l), indicating that CLECs may promote tumour growth by supporting vessel 185 
branching. 186 
CLECs express a unique set of markers 187 
To further understand the nature of tumour CLECs (T_CLECs), we performed single-cell 188 
RNA sequencing (scRNA-seq) on isolated T_CLECs in the mouse glioma model. Single-189 
cell transcriptome analysis using Smart-seq2 25 identified that the gene expression pattern 190 
of T_CLECs was similar to lineage-negative tumour endothelial cells (T_ECs), but not 191 
to tumour macrophages (T_MACs), as determined by UMAP (Uniform Manifold 192 
Approximation and Projection) analysis (Fig. 5a). Single-cell differential expression 193 
(SCDE) analysis 26 confirmed that T_CLECs expressed typical endothelial markers, but 194 
lacked macrophage and myeloid cell markers (Fig. 5b). Unexpectedly, however, 195 
T_CLECs showed no Csf1r expression, despite carrying the Csf1r-lineage marker (Fig. 196 
5c). Beyond the overlapping gene expression pattern between T_CLECs and T_ECs, 197 
SCDE analysis identified a unique signature that can distinctly define the T_CLECs 198 
population; RNAs coding for 24 genes including three types of cell surface proteins 199 
(Aqp1: Aquaporin 1, Fabp4: Fatty acid binding protein 4, Kcnj8: Potassium voltage-200 
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 9 
gated channel subfamily j member 8) were significantly enriched in T_CLECs (Fig. 5d; 201 
Extended Data Fig. 6; Supplementary Table 1). Aqp1 is highly expressed in vascular 202 
endothelial cells and was reported to contribute to tumour growth and angiogenesis 27. 203 
Staining of lineage traced T_CLECs on fixed mouse glioma samples confirmed AQP1 204 
expression (Extended Data Fig. 7).  205 
The T_CLEC state is enriched for “Tip-like” and a lymphatic gene signature 206 
Gene set enrichment analysis (GSEA) identified that the T_CLEC state shows significant 207 
enrichment for a Tip-cell-like associated gene expression program (Fig. 5e), thus 208 
supporting the morphological observations and their functional importance for branching 209 
and tumour growth. Intriguingly, GSEA identified that T_CLECs were also enriched for 210 
lymphatic gene signatures (Fig. 5e). AUCell analysis 28 of scRNA-seq data from multiple 211 
human primary tumours identified subpopulations of endothelial cells that express the 212 
T_CLECs marker gene set (Fig. 5f-k, 442 out of 7314 ECs are candidates: 6.0%; 213 
Supplementary Table 2). These bona-fide T_CLECs were highly enriched in tip cell, 214 
neophalanx cell, lymphatic endothelial cell subpopulations and particularly abundant in 215 
human pancreatic cancer (Fig. 5k). Neophalanx endothelial cells, which express two pro-216 
angiogenesis markers, Glul (Glutamine synthetase) and Cxcl12 (C-X-C motif chemokine 217 
ligand 12) 29,30 have recently been identified in lung tumour-associated endothelial cell 218 
studies 31,32, and were proposed to line neo-vessels after termination of vessel sprouting. 219 
Together this data suggests that based on the transcriptional state, T_CLECs might have 220 
a supportive role in tumor vessel sprouting and remodeling. Detailed comparison with 221 
recent single cell RNA seq data on tumour endothelial cells in mouse and human tumours 222 
31 confirmed the Tip-like gene signature of T_CLECs, but also identified significant 223 
similarities with lymphatics (Fig. 5k). The latter is particularly surprising given that our 224 
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perfusion experiments with dextran clearly demonstrated that T_CLECs in the glioma 225 
model line blood vessels, not lymphatics.  226 
Acute recombination identifies a CLEC lineage in lymph nodes 227 
The transcriptional similarities between T_CLECs and lymphatic endothelial cells are 228 
noteworthy as blood endothelial cells, in particular in the brain environment, and 229 
lymphatic EC represent highly differentiated cell types. During vertebrate embryogenesis, 230 
lymphovenous specification sees common progenitor cells diverge in their differentiation 231 
to establish mature blood endothelium and lymphatic endothelium33. The apparent 232 
similarities could therefore suggest that T_CLECs represent an immature endothelial cell 233 
state with partially overlapping profiles of both immature blood and lymphatic cells. In 234 
this case, the expression of lymphatic genes would signify a return to an earlier cell state 235 
or potentially some level of transdifferentiation between the two endothelial cell states. 236 
The latter would imply a distant source of lymphatic endothelium as possible origin of 237 
CLECs. Indeed, when searching for CLECs in all organs, we observed selective 238 
endothelial labelling in lymph nodes, notably restricted to the periphery where specialized 239 
lymphatic endothelial cells form the floor of the subcapsular sinus (SCS, Fig. 6a). Bone-240 
marrow transplantation to eliminate the abundant Csfr1-lineage macrophage population 241 
highlighted the specific labelling of CLECs in lymph nodes (Fig. 6b). 242 
To gain more insight into the emergence of T_CLECs, we asked whether acute 243 
recombination could indicate their possible origin. Acute induction experiments (24h 244 
after single tamoxifen injection) illustrated that the Csf1r-expressing progenitors of this 245 
tumour endothelial cell population do not reside locally in pre-existing brain or the 246 
associated brain tumour vasculature (Extended Fig. 8). Close inspection however 247 
revealed GFP-positive endothelial cells with significant labelling 24h post-injection in 248 
the floor endothelial cells of the SCS of lymph nodes (Fig. 6c). The mTmG Cre-reporter 249 
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switches from red fluorescent protein expression to mEGFP expression upon 250 
recombination. Therefore, cells that acutely recombine, carry both GFP and Tomato 251 
expression until the latter is fully degraded. Strikingly, floor SCS endothelial cells 252 
exhibited both GFP and simultaneous Tomato expression, demonstrating recent 253 
recombination. FACS analysis confirmed the presence of double positive EC in lymph 254 
nodes, but not in brain or brain tumours. In fact, double positive cells for GFP and Tomato 255 
were not observed in the brain tumours at any stage, excluding the possibility of any acute 256 
or continuous local recombination of T_CLECs within the tumour microenvironment. 257 
Prox-1 staining confirmed the lymphatic nature of CLECs in the lymphnode, and 258 
demonstrated that only a subpopulation of lymphatic endothelial cells in the lymph node 259 
carry the Csfr1-lineage trace, the cells in the floor of the SCS (Fig. 6d). 260 
We decided to perform scRNA seq also on endothelial cells isolated from lymph nodes, 261 
assess gene expression and perform pseudotime analysis to understand differentiation of 262 
T_CLECs, T_EC, LN_CLECs (GFP positive) and LN_ECs (GFP negative) (Fig. 7a-f). 263 
We used the same Smart-seq2 platform for comparison to sequence another 384 cells of 264 
lymph node origin. After quality control (Fig. 7a), 89 cells EC, not Csfr1 lineage EC, and 265 
104 cells expressing GFP (Fig.7b) in the lymph nodes were selected for further analysis. 266 
Comparative analysis with recent mouse lymph node scRNA data34 confirmed that the 267 
LN_CLEC co-register with identified SCS floor cells (Extended Data Fig. 9a).  268 
Unlike T_CLECs, LN_CLECs also expressed Csf1r, in line with our finding of acute 269 
recombination in the SCS floor cells.  270 
UMAP based dimension reduction placed T_CLECs and T_EC closely together, as before, 271 
and also LN_CLEC and LN_EC co-cluster, although two additional distinct LN_EC 272 
clusters appear highly distinct and thus unrelated to any of the other cell types (Fig. 7c). 273 
Interestingly, some T_CLEC cluster with the LN_CLEC, suggesting that there is at least 274 
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some overlap in gene expression between the Csf1r lineage cells in the brain tumour and 275 
in the lymph nodes. Looking at relative expression levels of all genes in a heatmap 276 
comparing the lineage positive and negative EC from lymph nodes and tumours 277 
highlighted that differential expression is more prevalent than any overlap between 278 
tumour EC and LN EC (Fig. 7d). However, there are small number of genes like Pde4d, 279 
Robo1 and Itga9 that show higher expression in the two lineage positive populations in 280 
LN and tumour, compared to the lineage negative cells (Extended Data Fig. 9b). Itga9 is 281 
well known to be important in lymphatic development35, confirming again that T_CLECs 282 
carry some gene expression patterns normally associated with lymphatic EC. 283 
Nevertheless, despite the fact that only LN_CLEC appear to acutely recombine, 284 
differential gene expression analysis does not provide clear evidence for a lineage 285 
relationship between LN_CLEC and T_CLEC. 286 
 287 
T_EC and T_CLECs “co-evolve” during tumour growth, suggesting distinct origin 288 
To gain more insight into the differentiation state and possible route of differentiation, 289 
we next performed pseudotemporal ordering using Monocle36 (Fig. 7f). The Monocle 290 
inferred trajectory suggested equally distributed pseudotime values for T_CLECs and 291 
T_EC then LN_EC and finally LN_CLECs. When measuring single-cell gene expression 292 
diversity as surrogate for differentiation potential with the CytoTRACE algorithm37 293 
(higher score means more undifferentiated, stem-like), we observed again equal scores 294 
between T_CLECs and T_EC but lower cytoTRACE values for LN_EC and LN_CLECs 295 
(Fig. 7e-f). The equal scores between T_CLECs and T_ECs argue against a role of T_ECs 296 
as precursors for T_CLECs, independently confirming that T_CLECs are unlikely 297 
emerging through differentiation from the pre-existing brain tumour vasculature. 298 
However, the LN_CLECs display the lowest cytoTRACE scores (most differentiated). 299 
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Based on the cytoTRACE analysis, and its logic of developmental potential, it would 300 
seem unlikely that LN_CLEC are the origin of T_CLEC (Fig. 7e-f). Moreover, it appears 301 
that both lineage positive and negative EC in the lymph nodes are more differentiated 302 
than endothelial cells in the tumour. It is noteworthy that Monocle was designed for 303 
developmental questions, which are strictly unidirectional. Interestingly, when plotting 304 
CytoTRACE scores onto the Monocle trajectory (Fig. 7f), the right side shows higher 305 
scores (T_CLEC and T_EC) and the left side (darker blue) lower scores (LN_CLECs 306 
lowest), being in line with pseudotime. This again predicts that LN_CLECs represent an 307 
end state rather than the origin. In summary, these data predict that during tumour growth, 308 
the T_EC and T_CLECs coevolve from a distinct origin to then share many aspects of 309 
their gene expression and biology, yet with a few very distinct gene profiles.  310 
 311 
DISCUSSION 312 
 In this study, using inducible Csf1r lineage tracing in adult mice intended to study 313 
macrophage recruitment during glioma development, we identify a distinct endothelial 314 
cell lineage that forms up to 10% of the tumour vasculature in adult mice. Selective 315 
experimental depletion of this Csf1r endothelial cell lineage demonstrated a role in 316 
promoting vascular branching and tumour growth. Through a combination of genetic 317 
lineage tracing, longitudinal live two-photon imaging, and single cell analysis, we find 318 
that these cells arise during tumour progression, adopt dynamic endothelial phenotypes 319 
including tip cell characteristics, and express common endothelial as well as unique 320 
markers that can also be found in patient-derived tumour endothelium.  321 
 Csf1r is a well-known regulator of monocyte/ macrophage differentiation 38,39, but is 322 
also important for yolk sac hematopoiesis and progenitor cell differentiation. Klotz and 323 
coworkers reported that Csf1r-expressing cells in the mouse embryo contribute to Prox1-324 
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positive lymphatic endothelial cells in the cardiac lymphatic vasculature 40. Moreover, a 325 
recent report identified that Csf1r-expressing erythro-myeloid progenitors from the early 326 
embryonic yolk-sac could give rise to intraembryonic endothelial cells in mouse 327 
development41. Csf1r is also expressed in EPCs, such as colony forming unit-Hill cells 328 
and circulating angiogenic cells 42. In the adult however, Csf1r is not expressed in the 329 
mature endothelium of blood and lymphatic vessels, but continues to drive recruitment 330 
and expansion of myeloid cells in inflammation, ischemia and tumour growth 43. 331 
Intriguingly, Csf1r itself is no longer expressed in the Csf1r lineage cells within the 332 
tumour and acute recombination of endothelial cells 24h after tamoxifen injection fails to 333 
label cells in the tumour vasculature. These results raise the possibility that a Csf1r-334 
expressing cell population of endothelial nature or potential is present elsewhere in the 335 
body, recombines upon tamoxifen injection and is recruited to the tumour vasculature 336 
where it differentiates into blood endothelium to contribute to tumour angiogenesis. 337 
Alternatively, the fact that Csf1r expression is not detected in isolated tumour CLECs 338 
could also indicate that the Cre-line is leaky and gives rise to labelled cells through 339 
stochastic recombination. In that case, one would expect the labelled cells to populate any 340 
part of the vasculature and be otherwise indistinguishable from the unlabelled tumour EC. 341 
Single cell analysis however identifies a unique gene expression signature beyond the 342 
large number of genes that are co-expressed in T_CLEC and T_EC, and demonstrates 343 
that T_CLEC are distinctly enriched in tip-cell and neo-phalanx cell populations. Thus, 344 
labelled cells show distinct phenotypes, location and expression patterns, ruling out 345 
purely stochastic recombination events. Furthermore, such stochastic recombination 346 
within the tumour vasculature would necessitate that we identify acutely labelled cells 347 
marked by co-expression of Tomato and GFP. As we failed to identify such cells at any 348 
timepoint during tumour growth, and also could detect the emergence of T_CLECs in 349 
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mice only injected with tamoxifen before tumour implantation, the cumulative evidence 350 
would suggest that T_CLECs originate outside of the tumour and also that the progenitor 351 
population resides outside of the brain. Despite all our efforts, the present work fails to 352 
provide ultimate and definitive proof of the true origin of T_CLECs, but arrives at a clear 353 
direction and working hypothesis for future studies. In search of their origin and a 354 
potential progenitor population, we imaged and analysed all organs by FACS. We 355 
performed bone-marrow transplantation, performed splenectomy and examined the entire 356 
mouse by fluorescence stereomicroscopy after clearing to identify regions of 357 
recombination. The results of bone-marrow transplantation effectively ruled out EPC or 358 
any other known progenitors that may be found in circulation, including 359 
transdifferentation from macrophages. Four independent observations placed a spotlight 360 
on lymphatics, and the lymph nodes in particular. First, the only bonafide Csf1r lineage 361 
endothelial cell population that we could identify outside of the tumours, including after 362 
complete reconstitution of the bone marrow by wildtype bone marrow, was found in the 363 
subcapsular sinus of the lymph nodes. Here the floor cells, specialized lymphatic 364 
endothelial cells that we identify as GFP and Csf1r positive line the capsule in lymph 365 
nodes in close apposition to the Csf1 expressing ceiling cells. Second, after acute 366 
tamoxifen injection the cells in the floor of the subcapsular sinus are uniquely double 367 
positive for Tomato and GFP, demonstrating acute and likely local recombination. Third, 368 
single cell RNAseq of T-CLECs identified lymphatic markers including the lymphatic 369 
master regulator Prox1 co-expressed with blood endothelial markers, and SCDE placed 370 
T_CLECs close to lymphatic endothelial cells from various mouse tumour models in 371 
recently published datasets. And finally, CLECs can also be found in lymphatics in 372 
subcutaneous tumour models and in skin. These independent observations clearly make 373 
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the SCS floor cells prime candidates for the origin of T_CLECs, but future work will be 374 
necessary for a possible direct demonstration of this link. 375 
In developmental studies, lineage relationships have recently been studied by scRNAseq 376 
data sets through pseudotime analysis. In particular the CytoTRACE analysis can be 377 
useful to estimate the degree of differentiation of cell populations and thereby also predict 378 
their stemness 37. Our comparative analysis of endothelial cells isolated from tumour and 379 
lymph nodes assigned the highest differentiation scores to cells in the lymph node, and 380 
lower values to the EC in tumour, including T_CLECs. Accordingly, the cells in the floor 381 
of the SCS that carry the lineage label would rather be assumed at the end of a 382 
differentiation process rather than progenitors for other populations such as the T_CLECs. 383 
Whether however such algorithms are suitable to determine the potential of endothelial 384 
cells to become activated and possibly transdifferentiate is unclear. In particular given the 385 
altered environmental context of EC within a growing tumour compared to a vascular bed 386 
in homeostasis. The combined monocle36 and cytoTRACE analysis would fit with a 387 
general level of dedifferentiation of endothelial cells within the tumour microenvironment, 388 
and therefore a co-evolution of the cell states of both T_EC and T_CLEC. It is likely that 389 
pseudotemporal ordering of endothelial cells in a reactivation state will always show the 390 
reactivated cells, like in the tumour environment as less differentiated. Indeed, recent 391 
work studying the effect of chronic hypoxia on brain endothelium illustrated the wide 392 
range of reactivation, in particular noting a strong increase in tip cell population amongst 393 
the brain endothelial cells44. The current assumption states that these new tip cells arise 394 
under hypoxia from pre-existing brain endothelial cells, and possibly emerge from 395 
particular endothelial subpopulations. In the absence of lineage tracing, an alternative 396 
possibility, raised by our current observation in tumour angiogenesis, could be that new 397 
tip cells arise at least in part elsewhere, and are recruited to the hypoxic vessel areas.  398 
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More work on vascular single cell analysis will be required to establish the fundamental 399 
principles of endothelial activation and their interpretation for the different tissue 400 
challenges that require vascular adaptations. 401 
Angiogenesis is essential for tumour growth, and contributes to metastasis 45,46. Early 402 
hopes that targeting tumour angiogenesis may prove uniquely selective and effective as 403 
anti-tumour treatment have, however, been disappointing. Intense research efforts 404 
therefore currently focus on understanding reasons and mechanisms for resistance to anti-405 
angiogenic therapy, and identifying new cellular and molecular targets to effectively 406 
modify the tumour vasculature 47. Intravital imaging shows that T_CLECs arise during 407 
tumour progression, adopt endothelial phenotypes with tip cell characteristics and line 408 
perfused vascular tubes. Consistent with this observation, AUCell analysis of scRNA-seq 409 
data in human samples identifies that T_CLECs signatures are highly enriched in tip cell 410 
subpopulation. A recent study using single-cell transcriptome analysis revealed that anti-411 
VEGF (vascular endothelial growth factor) treatment reduces the proportion of 412 
endothelial tip-like cells in a tumour xenografts 48. How CLECs affect the outcome of 413 
anti-angiogenic treatment will be important to investigate in the future. Considering that 414 
T_CLECs prominently express Vegfr3, even more so than regular endothelial cells in the 415 
tumour, we can speculate that T_CLECs are resistant to anti-VEGFR2 treatment, and 416 
possibly escape treatment through the activity of VEGFR3. If so CLECs may adversely 417 
affect anti-angiogenic therapy targeting VEGFR2 selectively. Tumour blood vessels are 418 
generally highly tortuous and the branching pattern is greatly different from normal blood 419 
vessels. Our results from the selective targeting of CLECs in the mouse glioma model 420 
show that CLECs ablation decreases both vessel branching and tumour growth. Thus, in 421 
the absence of CLEC, the dysmorphic vascular phenotype in tumours appears exacerbated, 422 
suggesting that CLECs support the formation of a highly branched vascular network, 423 
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which in turn better promotes tumour growth. Future work will be required to identify the 424 
true origin of T_CLECs and to extend this functional analysis to fully appreciate the 425 




Mice  430 
Mice expressing both the Csf1r-Mer-iCre-Mer transgene (Csf1r-Mer2.Cre) 17 and the 431 
RosamTmG Cre recombination reporter 18 were generated by breeding. Mice carrying the. 432 
Endothelial specific Cdh5-Dre mice 24 were mated with Csf1r-Mer2.Cre mice and 433 
Rosa26-RSR-LSL-tdTomato mice 23 to obtain Cdh5-Dre:: Csf1r-Mer2.Cre:: Rosa26-RSR-434 
LSL-tdTomato mice (DreMer2.CretdTomato) that allows combinatorial genetics as a tool for 435 
CLECs tracing.  Endothelial specific Cdh5-Dre mice were mated with Csf1r-Mer2.Cre 436 
mice and Rosa26-RSR-mTmG-DTR mice to obtain Cdh5-Dre:: Csf1r-Mer2.Cre:: Rosa26-437 
RSR-mTmG-DTR mice (DreMer2.CremTmG-DTR) that allows for selective tracing and 438 
ablation of CLECs. Rosa26-RSR-mTmG-DTR mice were designed by Dr. Fabio Stanchi 439 
and generated by the team of Dr. Ralf Kühn at the Max Delbrück Center in Germany. All 440 
mouse strains were maintained on C57BL/6J background. Animal housing and all 441 
experimental procedures were approved by the Institutional Animal Care and Research 442 
Advisory Committee of the KU Leuven (085/2016).  443 
Cell lines 444 
CT2A, GL261 glioma cell lines and B16F1 melanoma cell line were cultured in DMEM 445 
(Life Technologies) supplemented with 10% FBS (Life Technologies), 1% penicillin/ 446 
streptomycin (Life Technologies) and 1% glutamine (Life Technologies). Spheroids were 447 
obtained by seeding the glioma cells for 48h on non-adherent culture dishes. Spheroids 448 
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of 200- 250µm were selected for implantation. 449 
Intravital imaging on mouse gliomas  450 
Surgery for tumor implantation, installation of cranial windows and in vivo imaging were 451 
performed as described previously 16. Briefly, 8– 12-weeks-old mice were anesthetized 452 
with ketamine/ xylazine and a craniotomy was performed on the parietal bone. Spheroids 453 
of CT2A or GL261 cells modified to express the blue fluorescent protein TagBFP 50 were 454 
injected in the exposed parietal brain cortex, which was then sealed by cementing a glass 455 
coverslip to the bone surrounding the craniotomy. After surgery, mice were injected 456 
intraperitoneally with tamoxifen (65 μg/g body weight) every 5 days. For CLECs 457 
depletion, mice were injected intraperitoneally with diphtheria toxin (4 ng/g body weight) 458 
the next day after tamoxifen induction. Longitudinal in vivo imaging of growing tumors 459 
was performed in mice under isoflurane anesthesia using a SP8 upright microscope (Leica 460 
Microsystems) equipped with a HCX IRAPO L25x/0.95 water objective and a Titanium: 461 
Sapphire laser (Vision II, Coherent Inc.) tuned at 925 nm. Humane end-point of 462 
experiments was applied if animals lost 15-20% of their original weight or shown evident 463 
signs of distress. 464 
Immunofluorescence imaging  465 
Mice anesthetized with ketamine/ xylazine were perfused through the heart with 15 ml of 466 
ice-cold PBS, followed by 10 ml of 2% PFA in PBS. Tumour tissues or organs were 467 
harvested and fixed overnight in 4% PFA. For tumour tissues, sections (200 µm-thick) 468 
were prepared with a vibratome 650V (Thermo Scientific). For organ samples, frozen 469 
sections (10 µm-thick) were prepared with a cryostat NX70 (Thermo Scientific). For 470 
immunofluorescence imaging studies, the PFA-fixed sections were blocked and 471 
permeabilized in TNBT (0.1 M Tris, pH 7.4, 150 mM NaCl, 0.5% blocking reagent from 472 
Perkin Elmer, 0.5% Triton X‐100) for 4h at room temperature. Sections were incubated 473 
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with antibodies against CDH5 (1:25, AF1002, R&D), CD31 (1:100, ab28364, Abcam), 474 
F4/80 (1:100, MF48000, Invitrogen), CD45 (1:100, 550539, BD Pharmingen),  CD169 475 
(1:100, 142401, Biolegend), PROX1 (1:200, 11-002, Angiobio), AQP1 (1:4000, AB2219, 476 
Millipore), LYVE1 (1:100, 50-0433-80, eBioscience) diluted in TNBT buffer overnight 477 
at 4°C, washed in TNT buffer (0.1 M Tris pH 7.4; 150 mM NaCl, 0.5% Triton X‐100) 478 
and incubated with an Alexa Fluor conjugated antibodies (1:200, ThermoFisher 479 
Scientific). Sections were washed and mounted in fluorescent mounting medium (Dako). 480 
Images were obtained with a Leica TCS SP8 confocal microscope. 481 
Flow cytometric analysis  482 
Mice were anesthetized with ketamine/ xylazine, then tumour tissues or organs were 483 
harvested and incubated with PBS containing 1mg/ml collagenase I (Gibco), 2 mg/ ml 484 
Dispase I (Gibco), 100ug/ml DNase I (Roche) and 2 mM CaCl2 for 30 min at 37 °C. After 485 
incubation, the digested tissue was passed through a cell strainer and then washed by PBS 486 
including 2% FBS. For red cell exclusion, we incubated samples with red cell lysis buffer 487 
(Sigma) for 5 min at 37 °C and then washed by PBS including 2% FBS and 2 mM EDTA. 488 
Cells were stained with the following monoclonal antibodies: PE/ Cy7 anti-CD45 489 
(552848, BD), APC anti-CD31 (561814, BD). Data acquisition was performed with BD 490 
FACSVerse and analysis was performed with BD FACSuite software, and FlowJo 491 
software.  492 
Mouse melanoma model 493 
Mice (8–12-weeks-old) were anesthetized with ketamine/ xylazine and then 1x106 B16F1 494 
melanoma cells in PBS were implanted into the right flank region of the mice. B16F1 495 
melanomas were removed from mice 12 days after implantation for immunofluorescent 496 
imaging studies and flow cytometric analysis. Mice were injected intraperitoneally with 497 
tamoxifen (65 μg/g body weight) 4 time/ 2 weeks before tumour implantation and then 498 
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intraperitoneally with tamoxifen (65 μg/g body weight) every 5 days after tumour 499 
implantation. 500 
Single cell isolation and RNA-sequencing 501 
Single cells were sorted (BD FACSAriaIII) in 96 well plates (VWR) containing 2 μL of 502 
PBS including 0.2% Triton X-100 and 4U of RNase inhibitor (Takara) per well. Plates 503 
were properly sealed and spun down at 2000 g for 1 min before storing at −80°C. Whole 504 
transcriptome amplification was performed with a modified SMART-seq2 protocol as 505 
described previously 25, using 20 instead of 18 cycles of cDNA amplification. PCR 506 
purification was realized with a 0.8:1 ratio (ampureXP beads:DNA). Amplified cDNA 507 
quality was monitored with a high sensitivity DNA chip (Agilent) using the Bioanalyzer 508 
(Agilent). Sequencing libraries were performed using the Nextera XT kit (Illumina) as 509 
described previously 25, using 1/4th of the recommended reagent volumes and 1/5th of 510 
input DNA with a tagmentation time of 9 min. Library quality was monitored with a high 511 
sensitivity DNA chip (Agilent) using the Bioanalyzer (Agilent). Indexing was performed 512 
with the Nextera XT index Kit V2 (A-D). Up to 4 x 96 single cells were pooled per 513 
sequencing lane. Samples were sequenced on the Illumina NextSeq 500 platform using 514 
75bp single-end reads. 515 
scRNA-sequencing data analysis 516 
BAM files were converted to merged, demultiplexed FASTQ files, cleaned using fastq-517 
mcf (ea-utils r819), and QC checked with FastQC (0.11.4). Reads were then mapped to 518 
the mouse genome (mm18) using STAR (2.4.1b) and quantified with Subread (1.4.6-p2). 519 
Cells with less than 100,000 reads and/or 500 genes expressed, more than 20% 520 
mitochondrial reads, and less than an average expression level of 3.0 of about 80 521 
housekeeping genes 51 were discarded. 469 cells passed these stringent quality criteria. 522 
Winsorized Highly Variable genes (HVGs) were identified for tumor derived 523 
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macrophages (T_MACs), endothelial cell (T_ECs) and Csf1r lineage endothelial cells 524 
(T_CLECs) 26. These cells were then clustered based on HVG expression using non-525 
negative matrix factorization as dimension reduction approach (run=40, rank=10, in MeV 526 
4.8.1). The “best fit” (numbers of clusters) was chosen based on the highest cophenetic 527 
correlation coefficient. Next, Single-cell Differential Expression analysis (SCDE) was 528 
performed between the different NMF-clusters using the global gene expression matrix 529 
26. Expression values were library-size-factor-normalized (DESeq) and log2 transformed 530 
(log2+1). T_MAC, T_EC, T_CLEC and LN_CLECS, LN_EC, T_CLEC, T_EC cells 531 
were projected into a two-dimensional space using Uniform Manifold Approximation and 532 
Projection (dims=15, resolution = 0.4) based on 5k most variable features (Seurat 533 
pipeline) 52. Monocle (2.14) based trajectory analysis was performed on T_CLEC, T_EC, 534 
LN_CELC and LN_EC (total=454 cells) taking into account n=790 m3Drop genes. The 535 
same data set was subjected to CytoTRACE analysis using the online tool 536 
(https://cytotrace.stanford.edu/) 37. 537 
 538 
AUCell analysis of human scRNA-seq data in multiple tumours 539 
The droplet-based scRNA-seq data of 4 human tumour types were downloaded from 540 
publicly available sources including lung cancer (ArrayExpress: E-MTAB-6149 and E-541 
MTAB-6653)53, PDAC (GSA: CRA001160)54, liver cancer (GEO: GSE125449)55, and 542 
BCC (GEO: GSE123814)56. These datasets were processed and clustered per tumour type 543 
using Seurat (v3.0.4) package, and the endothelial cell clusters were identified using 544 
marker genes (CLDN5, VWF, PECAM1). The resulting endothelial cell data were pooled 545 
together and aligned using anchor-based canonical correlation analysis (CCA) to mitigate 546 
the difference related to distinct tumor types and scRNA-seq technologies. Initial graph-547 
based clustering identified 10 clusters including 3 potential doublet clusters as predicted 548 
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by DoubleFinder (v2), which were subsequently removed before second round of 549 
clustering. The resulting 8 clusters consisting of 7314 endothelial cells were annotated 550 
based on known marker genes, and their CLECs signature were calculated using AUCell 551 
package (v1.6.1). The threshold of AUC score was chosen at the peak of the right modal, 552 
and the percentage of putative CLECs were calculated for different subtypes and their 553 
tumour type of origin. 554 
Generation of bone marrow chimeras  555 
Recipient 8-10-weeks-old mice were lethally irradiated (9.5 Gy) and then intravenously 556 
injected with 1x107 bone marrow cells from donor mice 16 h later. Tumour implantation 557 
experiments were initiated 8 weeks after bone marrow reconstitution. Reconstitution rate 558 
was determined using flow cytometric analysis in the peripheral blood. 559 
Surgical removal of the spleen 560 
Mice (8–12-weeks-old) were anesthetized with ketamine/ xylazine and then the spleen 561 
was gently taken out from the connective tissue, while cauterizing associated vessels. The 562 
incision was thereafter sutured. These procedures were performed as described previously 563 
57. 564 
Vessel morphology analysis 565 
Confocal images of the tumour vasculature were analyzed for two-dimensional vessel 566 
area, network length and number of network bifurcation points. The tdTomato and GFP 567 
channels were merged and a Gaussian blur filter as well as Otsu thresholding was applied 568 
to obtain binary vessel mask for sectional area estimation. To obtain the vessel network, 569 
a semi-automatic multicut workflow from ilastik 58 was applied to all images. The 570 
segmented vessels were skeletonized and converted into a network graph with nodes and 571 
edges by using the Python package ImagePy 59. The lengths of network edges were 572 
summed up to obtain the total network length for each image, all nodes with a degree of 573 
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three or more were counted as bifurcations. 574 
Statistics 575 
Statistical analyses of data were performed with GraphPad Prism 7.0 software. All data 576 
are shown as the means ± standard deviations. Differences were assessed using a two-577 
tailed unpaired Mann-Whitney’s U test or two-tailed unpaired Welch’s correction. 578 
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The computational code (R) used for scRNA-seq analysis is based on already published 599 
pipelines (see Material and Methods) and available upon request. 600 
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Differences were assessed using either a two-tailed unpaired Mann-Whitney’s or two-607 
tailed unpaired t-test with Welch correction. All planned comparisons were considered 608 
stand-alone and were not corrected for multiple testing. 609 
 610 
REFERENCES 611 
1 Asahara, T. et al. Isolation of putative progenitor endothelial cells for 612 
angiogenesis. Science 275, 964-967, doi:10.1126/science.275.5302.964 (1997). 613 
2 Shi, Q. et al. Evidence for circulating bone marrow-derived endothelial cells. 614 
Blood 92, 362-367 (1998). 615 
3 Asahara, T. et al. Bone marrow origin of endothelial progenitor cells responsible 616 
for postnatal vasculogenesis in physiological and pathological neovascularization. 617 
Circ Res 85, 221-228, doi:10.1161/01.res.85.3.221 (1999). 618 
4 Peters, B. A. et al. Contribution of bone marrow-derived endothelial cells to 619 
human tumor vasculature. Nat Med 11, 261-262, doi:10.1038/nm1200 (2005). 620 
5 Rafii, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and 621 
haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev 622 
Cancer 2, 826-835, doi:10.1038/nrc925 (2002). 623 
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted June 11, 2021. ; https://doi.org/10.1101/2021.06.09.447719doi: bioRxiv preprint 
 26 
6 Rafii, S. & Lyden, D. Therapeutic stem and progenitor cell transplantation for 624 
organ vascularization and regeneration. Nat Med 9, 702-712, 625 
doi:10.1038/nm0603-702 (2003). 626 
7 Religa, P. et al. Presence of bone marrow-derived circulating progenitor 627 
endothelial cells in the newly formed lymphatic vessels. Blood 106, 4184-4190, 628 
doi:10.1182/blood-2005-01-0226 (2005). 629 
8 Kerjaschki, D. et al. Lymphatic endothelial progenitor cells contribute to de novo 630 
lymphangiogenesis in human renal transplants. Nat Med 12, 230-234, 631 
doi:10.1038/nm1340 (2006). 632 
9 Purhonen, S. et al. Bone marrow-derived circulating endothelial precursors do not 633 
contribute to vascular endothelium and are not needed for tumor growth. Proc 634 
Natl Acad Sci U S A 105, 6620-6625, doi:10.1073/pnas.0710516105 (2008). 635 
10 Kerbel, R. S. et al. Endothelial progenitor cells are cellular hubs essential for 636 
neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition 637 
but not adenomas. Proc Natl Acad Sci U S A 105, E54; author reply E55, 638 
doi:10.1073/pnas.0804876105 (2008). 639 
11 Basile, D. P. & Yoder, M. C. Circulating and tissue resident endothelial progenitor 640 
cells. J Cell Physiol 229, 10-16, doi:10.1002/jcp.24423 (2014). 641 
12 Psaltis, P. J. & Simari, R. D. Vascular wall progenitor cells in health and disease. 642 
Circ Res 116, 1392-1412, doi:10.1161/CIRCRESAHA.116.305368 (2015). 643 
13 Fujisawa, T. et al. Endothelial Progenitor Cells Do Not Originate From the Bone 644 
Marrow. Circulation 140, 1524-1526, 645 
doi:10.1161/CIRCULATIONAHA.119.042351 (2019). 646 
14 Martinez-Murillo, R. & Martinez, A. Standardization of an orthotopic mouse 647 
brain tumor model following transplantation of CT-2A astrocytoma cells. Histol 648 
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted June 11, 2021. ; https://doi.org/10.1101/2021.06.09.447719doi: bioRxiv preprint 
 27 
Histopathol 22, 1309-1326, doi:10.14670/HH-22.1309 (2007). 649 
15 Zagzag, D. et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: 650 
association with angiogenesis, invasion, and progression. Cancer 88, 2606-2618 651 
(2000). 652 
16 Stanchi, F., Matsumoto, K. & Gerhardt, H. Imaging Glioma Progression by 653 
Intravital Microscopy. Methods Mol Biol 1862, 227-243, doi:10.1007/978-1-654 
4939-8769-6_16 (2019). 655 
17 Qian, B. Z. et al. CCL2 recruits inflammatory monocytes to facilitate breast-656 
tumour metastasis. Nature 475, 222-225, doi:10.1038/nature10138 (2011). 657 
18 Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global double-658 
fluorescent Cre reporter mouse. Genesis 45, 593-605, doi:10.1002/dvg.20335 659 
(2007). 660 
19 Mathivet, T. et al. Dynamic stroma reorganization drives blood vessel dysmorphia 661 
during glioma growth. EMBO Mol Med 9, 1629-1645, 662 
doi:10.15252/emmm.201607445 (2017). 663 
20 Raivich, G. et al. Regulation of MCSF receptors on microglia in the normal and 664 
injured mouse central nervous system: a quantitative immunofluorescence study 665 
using confocal laser microscopy. J Comp Neurol 395, 342-358, 666 
doi:10.1002/(sici)1096-9861(19980808)395:3<342::aid-cne6>3.0.co;2-2 (1998). 667 
21 Jin, S. et al. Interleukin-34 restores blood-brain barrier integrity by upregulating 668 
tight junction proteins in endothelial cells. PLoS One 9, e115981, 669 
doi:10.1371/journal.pone.0115981 (2014). 670 
22 Vanlandewijck, M. et al. A molecular atlas of cell types and zonation in the brain 671 
vasculature. Nature 554, 475-480, doi:10.1038/nature25739 (2018). 672 
23 Liu, Q. et al. Lung regeneration by multipotent stem cells residing at the 673 
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted June 11, 2021. ; https://doi.org/10.1101/2021.06.09.447719doi: bioRxiv preprint 
 28 
bronchioalveolar-duct junction. Nat Genet 51, 728-738, doi:10.1038/s41588-019-674 
0346-6 (2019). 675 
24 Tang, M. et al. Simultaneous quantitative assessment of two distinct cell lineages 676 
with a nuclear-localized dual genetic reporter. J Mol Cell Cardiol 146, 60-68, 677 
doi:10.1016/j.yjmcc.2020.07.002 (2020). 678 
25 Picelli, S. et al. Full-length RNA-seq from single cells using Smart-seq2. Nat 679 
Protoc 9, 171-181, doi:10.1038/nprot.2014.006 (2014). 680 
26 Kharchenko, P. V., Silberstein, L. & Scadden, D. T. Bayesian approach to single-681 
cell differential expression analysis. Nat Methods 11, 740-742, 682 
doi:10.1038/nmeth.2967 (2014). 683 
27 Saadoun, S., Papadopoulos, M. C., Hara-Chikuma, M. & Verkman, A. S. 684 
Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene 685 
disruption. Nature 434, 786-792, doi:10.1038/nature03460 (2005). 686 
28 Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. 687 
Nat Methods 14, 1083-1086, doi:10.1038/nmeth.4463 (2017). 688 
29 Eelen, G. et al. Role of glutamine synthetase in angiogenesis beyond glutamine 689 
synthesis. Nature 561, 63-69, doi:10.1038/s41586-018-0466-7 (2018). 690 
30 Zhang, M. et al. CXCL12 enhances angiogenesis through CXCR7 activation in 691 
human umbilical vein endothelial cells. Sci Rep 7, 8289, doi:10.1038/s41598-017-692 
08840-y (2017). 693 
31 Goveia, J. et al. An Integrated Gene Expression Landscape Profiling Approach to 694 
Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. 695 
Cancer cell 37, 21-36 e13, doi:10.1016/j.ccell.2019.12.001 (2020). 696 
32 Rohlenova, K. et al. Single-Cell RNA Sequencing Maps Endothelial Metabolic 697 
Plasticity in Pathological Angiogenesis. Cell Metab 31, 862-877 e814, 698 
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted June 11, 2021. ; https://doi.org/10.1101/2021.06.09.447719doi: bioRxiv preprint 
 29 
doi:10.1016/j.cmet.2020.03.009 (2020). 699 
33 Yang, Y. & Oliver, G. Development of the mammalian lymphatic vasculature. 700 
The Journal of clinical investigation 124, 888-897, doi:10.1172/JCI71609 (2014). 701 
34 Fujimoto, N. et al. Single-cell mapping reveals new markers and functions of 702 
lymphatic endothelial cells in lymph nodes. PLoS biology 18, e3000704, 703 
doi:10.1371/journal.pbio.3000704 (2020). 704 
35 Bazigou, E. et al. Integrin-alpha9 is required for fibronectin matrix assembly 705 
during lymphatic valve morphogenesis. Developmental cell 17, 175-186, 706 
doi:10.1016/j.devcel.2009.06.017 (2009). 707 
36 Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed 708 
by pseudotemporal ordering of single cells. Nature biotechnology 32, 381-386, 709 
doi:10.1038/nbt.2859 (2014). 710 
37 Gulati, G. S. et al. Single-cell transcriptional diversity is a hallmark of 711 
developmental potential. Science 367, 405-411, doi:10.1126/science.aax0249 712 
(2020). 713 
38 Tushinski, R. J. et al. Survival of mononuclear phagocytes depends on a lineage-714 
specific growth factor that the differentiated cells selectively destroy. Cell 28, 71-715 
81, doi:10.1016/0092-8674(82)90376-2 (1982). 716 
39 Dai, X. M. et al. Targeted disruption of the mouse colony-stimulating factor 1 717 
receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, 718 
increased primitive progenitor cell frequencies, and reproductive defects. Blood 719 
99, 111-120, doi:10.1182/blood.v99.1.111 (2002). 720 
40 Klotz, L. et al. Cardiac lymphatics are heterogeneous in origin and respond to 721 
injury. Nature 522, 62-67, doi:10.1038/nature14483 (2015). 722 
41 Plein, A., Fantin, A., Denti, L., Pollard, J. W. & Ruhrberg, C. Erythro-myeloid 723 
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted June 11, 2021. ; https://doi.org/10.1101/2021.06.09.447719doi: bioRxiv preprint 
 30 
progenitors contribute endothelial cells to blood vessels. Nature 562, 223-228, 724 
doi:10.1038/s41586-018-0552-x (2018). 725 
42 Hirschi, K. K., Ingram, D. A. & Yoder, M. C. Assessing identity, phenotype, and 726 
fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 28, 1584-1595, 727 
doi:10.1161/ATVBAHA.107.155960 (2008). 728 
43 Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-729 
associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14, 730 
399-416, doi:10.1038/nrclinonc.2016.217 (2017). 731 
44 Heng, J. S. et al. Hypoxia tolerance in the Norrin-deficient retina and the 732 
chronically hypoxic brain studied at single-cell resolution. Proceedings of the 733 
National Academy of Sciences of the United States of America 116, 9103-9114, 734 
doi:10.1073/pnas.1821122116 (2019). 735 
45 Folkman, J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 736 
1182-1186 (1971). 737 
46 Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967-738 
974, doi:10.1038/nature04483 (2005). 739 
47 Welti, J., Loges, S., Dimmeler, S. & Carmeliet, P. Recent molecular discoveries 740 
in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 123, 3190-741 
3200, doi:10.1172/JCI70212 (2013). 742 
48 Zhao, Q. et al. Single-Cell Transcriptome Analyses Reveal Endothelial Cell 743 
Heterogeneity in Tumors and Changes following Antiangiogenic Treatment. 744 
Cancer Res 78, 2370-2382, doi:10.1158/0008-5472.CAN-17-2728 (2018). 745 
49 Bazigou, E. et al. Genes regulating lymphangiogenesis control venous valve 746 
formation and maintenance in mice. The Journal of clinical investigation 121, 747 
2984-2992, doi:10.1172/JCI58050 (2011). 748 
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted June 11, 2021. ; https://doi.org/10.1101/2021.06.09.447719doi: bioRxiv preprint 
 31 
50 Subach, O. M. et al. Conversion of red fluorescent protein into a bright blue probe. 749 
Chem Biol 15, 1116-1124, doi:10.1016/j.chembiol.2008.08.006 (2008). 750 
51 Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by 751 
single-cell RNA-seq. Science 352, 189-196, doi:10.1126/science.aad0501 (2016). 752 
52 Stuart, T. et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888-753 
1902 e1821, doi:10.1016/j.cell.2019.05.031 (2019). 754 
53 Lambrechts, D. et al. Phenotype molding of stromal cells in the lung tumor 755 
microenvironment. Nat Med 24, 1277-1289, doi:10.1038/s41591-018-0096-5 756 
(2018). 757 
54 Peng, J. et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and 758 
malignant progression in pancreatic ductal adenocarcinoma. Cell Res 29, 725-738, 759 
doi:10.1038/s41422-019-0195-y (2019). 760 
55 Ma, L. et al. Tumor Cell Biodiversity Drives Microenvironmental 761 
Reprogramming in Liver Cancer. Cancer Cell 36, 418-430 e416, 762 
doi:10.1016/j.ccell.2019.08.007 (2019). 763 
56 Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 764 
blockade. Nat Med 25, 1251-1259, doi:10.1038/s41591-019-0522-3 (2019). 765 
57 Cortez-Retamozo, V. et al. Origins of tumor-associated macrophages and 766 
neutrophils. Proc Natl Acad Sci U S A 109, 2491-2496, 767 
doi:10.1073/pnas.1113744109 (2012). 768 
58 Berg, S. et al. ilastik: interactive machine learning for (bio)image analysis. Nat 769 
Methods 16, 1226-1232, doi:10.1038/s41592-019-0582-9 (2019). 770 
59 Wang, A., Yan, X. & Wei, Z. ImagePy: an open-source, Python-based and 771 
platform-independent software package for bioimage analysis. Bioinformatics 34, 772 
3238-3240, doi:10.1093/bioinformatics/bty313 (2018). 773 
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted June 11, 2021. ; https://doi.org/10.1101/2021.06.09.447719doi: bioRxiv preprint 
 32 
 774 
FIGURE LEGENDS 775 
Fig. 1: Csf1r lineage endothelial cells (CLECs) contribute to perfused, dynamically 776 
sprouting and remodeling blood vessels in mouse glioma. a, Csf1r-Mer2.CremTmG: 777 
a mouse model for Csf1r-lineage tracing combining the tamoxifen-inducible Cre-driver 778 
under control of the Csf1r-promoter and the mTmG Cre-reporter. b, Timing schedule of 779 
glioma implantation, tamoxifen induction and in vivo imaging. c-f, Longitudinal 780 
intravital imaging of the tumour vasculature in CT2A mouse glioma of Csf1r-781 
Mer2.CremTmG by cranial window. Scale bar: 50 μm. c, In vivo imaging in 3 weeks 782 
glioma. Endothelial cells in red (tdTomato), Csf1r-labeled cells in green (GFP) and 783 
glioma cells in blue (BFP). d, Detail image of outlined square in Fig. 1c illustrating tracing 784 
of GFP-positive cells. White arrowheads, macrophages; blue arrowhead, CLECs at tip 785 
position. e, In vivo imaging of CLECs in 2 weeks glioma. Blue arrowheads, tip of 786 
endothelial cells. f, Visualization of blood vessels in 3 weeks glioma by Intravenous 787 
injection of dextran with texas red dye. Yellow arrowhead, bridging CLECs; orange 788 
arrowhead, tube formation by CLECs; blue arrowhead, CLECs at tip position. g-h, 789 
Counterstaining on PFA-fixed 4 weeks CT2A glioma sections of Csf1r-Mer2.CremTmG 790 
with indicated antibodies. Yellow arrows, CLECs. Scale bar: 25 μm.  791 
Fig. 2: Up to 10% of intra-tumour endothelium is comprised of CLECs not only in 792 
glioma, but also in other tumour types and locations. a-i, Quantification of the 793 
population of CLECs in glioma of Csf1r-Mer2.CremTmG mice. a, Gross appearance of 794 
sham control and 4 weeks CT2A glioma (Upper panel). Purple arrowhead, the area of 795 
capillary injection; blue arrowhead, glioma. Scale bar: 5 mm. Flow cytometric analysis 796 
of CLECs in sham control and 4 weeks CT2A glioma (Lower panel). b, In 3 weeks CT2A 797 
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glioma (n= 9), CLECs constitute 2.1 ± 1.0% of total endothelial cells (CD45-CD31+); in 798 
4 weeks CT2A glioma (n= 5), they make up 7.5 ± 1.6% of total endothelial cells. c, In 3 799 
weeks GL261 glioma (n= 5), CLECs constitute 1.5 ± 1.6% of total endothelial cells. d, 800 
Gross appearance of normal brain, sham control and 3 weeks CT2A glioma. Purple 801 
arrowhead, area of capillary injection. Scale bar: 5 mm. e-f, Quantification of the 802 
population of CLECs by flow cytometric analysis in brain and tumour samples. Bars 803 
represent mean ± s.d. *p<0.05, **p<0.01, ***p<0.001, ****P<0.0001. Two-tailed 804 
unpaired Mann-Whitney’ s U test. i-j, Analysis of CLECs in B16F1 melanoma in Csf1r-805 
Mer2.CremTmG mice. g, Counterstaining on PFA-fixed section of day12 melanoma with 806 
CDH5 antibody. Yellow arrows, CLECs. Scale bar: 50 μm. h, CLECs constitute 2.8 ± 807 
0.75% of total endothelial cells in day 12 melanoma (n=4).  808 
Fig. 3: CLECs do not originate from the bone marrow. a-b, Tamoxifen induction 809 
timing. b, Quantification of the population of tumour macrophagens (T_MACs: 810 
CD45+GFP+) and tumour CLECs (T_CLECs: CD45-CD31+GFP+) by flow cytometric 811 
analysis in tumour samples (n=4). Bars represent mean ± s.d. c, Fluorescent images of 812 
PFA-fixed 3 weeks CT2A glioma de of Csf1r-Mer2.CremTmG mice within 24 hours after 813 
tamoxifen induction. Scale bar: 100 μm. d-e, Flow cytometric analysis of CT2A-glioma 814 
in bone marrow chimeras. d, BMCsf1r-mer2.CremTmG: C57BL/6J mice are used as 815 
recipients and Csf1r-Mer2.CremTmG mice used as donors. Within the sorted myeloid 816 
cell population (BFP-CD45+), 32.3 ± 12.1% are GFP-positive in Csf1r-Mer2.CremTmG 817 
mice (n= 10), and 33.8 ± 6.9% are GFP-positive in bone-marrow transplanted BMCsf1r-818 
Mer2.CremTmG mice (n= 12). Among endothelial cell population (BFP-CD45-CD31+), 819 
4.3 ± 1.9% are GFP-positive in Csf1r-Mer2.CremTmG mice (n= 10), whereas no GFP-820 
positive endothelial cells are found in BMCsf1r-Mer2.CremTmG mice (n= 12). e, Csf1r-821 
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Mer2.CremTmG:: BMWT: Csf1r-Mer2.CremTmG are used as recipients and C57BL/6J 822 
as donors. Of the sorted myeloid cell population, 43.4 ± 11.3% GFP-positive cells are 823 
found in Csf1r-Mer2.CremTmG mice (n= 6), whereas 0.1 ± 0.1% GFP-positive cells are 824 
found in Csf1r-Mer2.CremTmG:: BMWT mice (n= 4). Of the endothelial cell population, 825 
10.5 ± 9.7% GFP-positive cells are found in Csf1r-Mer2.CremTmG mice (n= 6), and 9.3 826 
± 3.7% GFP-positive cells are found in Csf1r-Mer2.CremTmG:: BMWT mice (n= 4). 827 
Bars represent mean ± s.d. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Two-tailed 828 
unpaired Mann-Whitney’ s U test. e, Longitudinal intravial imaging of 2 weeks CT2A 829 
glioma of Csf1r-Mer2.CremTmG and Csf1r-Mer2.CremTmG :: BMWT mice. White 830 
arrows, CLECs. Scale bar: 50 μm.  831 
Fig. 4: Dual recombination lineage tracing and inducible depletion model identifies 832 
a role for CLECs in tumour blood vessel patterning supporting glioma growth. a, 833 
Cdh5-Dre: Csf1r-Mer2.Cre: RSR-LSL-tdTomato (DreMer2.CretdTomato): a genetic 834 
mouse model for CLEC selective tracing by dual recombination. b-c, Analysis in 835 
DreMer2.CretdTomato. b, Longitudinal intravital imaging of the tumour vasculature in 3 836 
weeks CT2A mouse glioma by Intravenous injection of FITC dextran. Yellow 837 
arrowheads, CLECs. Scale bar: 50 μm. c, ERG antibody counterstaining on PFA-fixed 838 
sections of 3 weeks CT2A glioma. Yellow arrows, CLECs. Scale bar: 50 μm. d, Cdh5-839 
Dre: Csf1r-Mer2.Cre: RSR-mTmG-DTR (DreMer2.CremTmG-DTR): a genetic mouse 840 
model for CLEC selective tracing and inducible ablation. DTR, diphtheria toxin receptor. 841 
e-m, Analysis in DreMer2.CremTmG-DTR. e, Longitudinal intravital imaging of the 842 
tumour vasculature in 3 weeks CT2A mouse glioma. Mer2.CremTmG, Csf1r-843 
Mer2.CremTmG. Yellow arrowheads, CLECs. f, Timing schedule of glioma implantation, 844 
tamoxifen induction and diphtheria toxin (DT) treatment. g, Gross appearance of 3 weeks 845 
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CT2A gliomas. Scale bar: 5 mm. h, Confocal images of PFA-fixed 3 weeks CT2A glioma 846 
sections. Yellow arrows, CLECs. Scale bar: 50 μm. i, Tumour weight at 3 weeks CT2A 847 
glioma. j-l, Analysis of PFA-fixed 3 weeks CT2A glioma sections. j, Tumour blood 848 
vessels area. k, Network length of tumour blood vessels. l, Number of bifurcations of 849 
tumour blood vessels. Bars represent mean ± s.d. *p<0.05, **p<0.01. Two-tailed unpaired 850 
Mann-Whitney’ s U test.  851 
Fig. 5: Single-cell analysis identifies a unique signature that defines the tumour 852 
CLECs. a-d, Single-cell RNA sequencing (scRNA-seq) analysis of tumour macrophages 853 
(T_MACs: CD45+GFP+, 79 cells), tumour endothelial cell (T_ECs: CD45-CD31+GFP-, 854 
78 cells), tumour CLECs (T_CLECs: CD45-CD31+GFP+, 141 cells) in 4 weeks CT2A 855 
glioma of Csf1r-Mer2.CremTmG mice. b, Gene expression of typical endothelial cell 856 
markers, macrophages and myeloid cell markers. c, Csf1r gene expression. d, Three 857 
characteristic genes expressed in T_CLECs. e, Enrichment of Tip-cell signature in 858 
T_CLECs compared to T_ECs as shown by GSEA. f-k, Analysis of scRNA-seq data of 859 
human endothelial cells from multiple primary tumours. f, UMAP plot of human 860 
endothelial cell subtypes. g, UMAP plot of human endothelial cells colour-coded for the 861 
tumour type of origins. h, UMAP plots with marker gene expression for each EC subtype. 862 
i, Heatmap of marker gene expression for each EC phenotype (each cell as a column and 863 
each gene as a row). j-k, AUCell analysis of 24 T_CLECs markers. j, T_CLECs 864 
subpopulation indicated (AUC>0.165) by red colored dots. k, Cell type-specific (left) and 865 
tumour type-specific (right) populations of T_CLECs. BCC, basal cell carninoma: PDAC, 866 
pancreatic ductal adenocarcinoma.  867 
Fig. 6: CLECs are linked to Prox1-positive lymphatic endothelium of the 868 
subcapsular sinus floor in lymph nodes. a, Fluorescent images of the indicated organs 869 
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of Csf1r-Mer2.CremTmG mice after multiple tamoxifen induction. Scale bar: 50 μm. b, 870 
Quantification of the population of CLECs in Csf1r-Mer2.CremTmG mice by flow 871 
cytmetric analysis. Of the endothelial cell population (CD45-CD31+), 9.8 ± 2.1% GFP-872 
positive cells are found in the axillary lymph node of Csf1r-Mer2.CremTmG mice (n= 873 
10). c, Counterstaining on PFA-fixed Inguinal lymph node of Csf1r-Mer2.CremTmG:: 874 
BMWT mice using PROX1 antibody within 24 hours after tamoxifen induction. Yellow 875 
arrowheads, GFP+tdTomato+PROX1+ cells in the floor of the subcapsular sinus. Scale 876 
bar 25 μm. d, Fluorescent images of PROX1 antibody counterstaining on PFA-fixed 877 
inguinal lymph node of Csf1r-Mer2.CremTmG::BMWT mice after multiple rounds of 878 
tamoxifen induction. Scale bar: 100 μm. Detailed image of square outlined in d. Yellow 879 
arrowheads, GFP+Prox1+ cells; blue arrowheads, GFP+Prox1- cells. h-k, Analysis of 880 
CT2A glioma in Prox1-CreERT2mTmG mice.  881 
Fig. 7: CLEC and EC heterogeneity in tumor and lymph node. a, Quality measures 882 
of 4 SMARTseq2 scRNA-seq. libraries: Csf1r-lineage endothelial cells (CLECs) and 883 
endothelial cells (ECs) isolated from tumor (T_) and lymph node (LN_). b, Violin plots 884 
show GFP expression per single cell. c, Uniform manifold approximation and projection 885 
(UMAP) of T_CLECs, T_ECs and LN_CLECs, LN_ECs. d, Heatmap shows the 20 most 886 
characteristic markers per cell population. e, UMAP colored by gene expression diversity 887 
(CytoTRACE score) and predicted ordering by CytoTRACE. f, Monocle based trajectory 888 
analysis of four cell populations, colored by pseudotime and CytoTRACE score.  889 
Extended Data Fig. 1: CLECs in mouse glioma express endothelial cell markers, but 890 
lack macrophage and myeloid cell markers.  Counterstaining on PFA-fixed 4 weeks 891 
CT2A glioma sections of Csf1r-Mer2.CremTmG with indicated antibodies. Lower panels 892 
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show the detail images of outlined squares in upper panels. Yellow arrowheads, CLECs; 893 
blue arrowheads, macrophages. Scale bar: 25 μm.  894 
Extended Data Fig. 2: CLECs contribute to lymphatic endothelium in the tumour 895 
environment. Fluorescent images of counterstaining on PFA-fixed section of day 12 896 
B16F1 melanoma under ear skin of Csf1r-Mer2.CremTmG mice using LYVE1 antibody. 897 
Lower panel indicates detail image of yellow outlined square in upper panel. Yellow 898 
arrow heads, CLECs. Scale bar: 100 μm.  899 
Extended Data Fig. 3: Reconstitution rate in bone marrow chimeras. Reconstitution 900 
rate was determined in peripheral blood 8 weeks after bone marrow transplantation. 901 
TdTomato-positive cells in blood of: C57BL/6J (0.3 ± 0.1%, n= 6), Csf1r-902 
Mer2.CremTmG (99.2 ± 0.5%, n= 7), BMCsf1r-Mer2.CremTmG (97.3 ± 1.6%, n= 13). 903 
Bars represent mean ± s.d. ****p<0.0001. Two-tailed unpaired Mann-Whitney’ s U test.  904 
Extended Data Fig. 4: CLECs do not originate from spleen. Surgical removal of 905 
spleen (splenectomy) was performed 3 weeks before glioma injection. CLECs isolated 906 
from CT2A glioma of sham control Csf1r-Mer2.CremTmG mice (n= 5) constitute 1.5 ± 907 
0.8 % of total tumour endothelial cell population, compared to 1.5 ± 0.5% found in Csf1r-908 
Mer2.CremTmG with splenectomy (n= 4). Bars represent mean ± s.d. Two-tailed 909 
unpaired Mann-Whitney’ s U test.  910 
Extended Data Fig. 5: CLECs locate at peripheral area of mouse glioma. a, 911 
Vibratome section (200 μm-thick) of 4 weeks CT2A glioma of Csf1r-Mer2.CremTmG:: 912 
BMWT mice. Scale bar: 1 mm. b, Fluorescent images of area outlined in a. Yellow 913 
arrowheads, CLECs. Scale bar: 100 μm.  914 
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Extended Data Fig. 6: 24 tumour CLECs markers in mouse glioma. SCDE analysis 915 
of scRNA-seq data of tumour macrophages (T_MACs: CD45+GFP+, n= 79), tumour 916 
endothelial cells (T_ECs: CD45-CD31+GFP-, n= 78), tumour CLECs (T_CLECs: CD45-917 
CD31+GFP+, n= 141) in 4 weeks CT2A glioma in Csf1r-Mer2.CremTmG mice. Bars 918 
represent mean ± s.d. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Two-tailed 919 
unpaired t-test with Welch correction.  920 
Extended Data Fig. 7: CLECs in glioma express AQP1. Counterstaining on PFA-fixed 921 
CT2A glioma of Csf1r-Mer2.CremTmG::BMWT mice using AQP1 antibody. Yellow 922 
arrowheads, T_CLECs; blue arrowheads, T_ECs. Scale bar: 25 μm.  923 
Extended Data Fig. 8: CLECs in glioma cannot be labelled by GFP within 24 hours 924 
after tamoxifen induction. a-b, Tamoxifen induction timing. b, Quantification of the 925 
population of tumour macrophagens (T_MACs: CD45+GFP+) and tumour CLECs 926 
(T_CLECs: CD45-CD31+GFP+) by flow cytometric analysis in tumour samples (n=4). 927 
Bars represent mean ± s.d. c, Fluorescent images of PFA-fixed 3 weeks CT2A glioma de 928 
of Csf1r-Mer2.CremTmG mice within 24 hours after tamoxifen induction. Scale bar: 100 929 
μm.  930 
Extended Data Fig. 9: CLEC and EC heterogeneity in tumor and lymph node . 931 
a, Heatmap shows the expression of n=91 fLECs markers in LN_CLEC, LN_EC, 932 
T_CLEC and T_EC single cells. b, Violin plots show the expression of 3 CLEC markers: 933 
Pde4d, Robo1 and Itga9. 934 
Supplemental Movie 1: Time-lapse in vivo imaging of Csf1r lineage endothelial tip 935 
cell in CT2A glioma of Csf1r-Mer2.CremTmG mice. Imaging was performed over 4 hours 936 
(1 frame/ 10 min). 937 
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 938 
Supplemental Movie 2: Time-lapse in vivo imaging of Csf1r lineage endothelial tip 939 
cell in CT2A glioma of Csf1r-Mer2.CremTmG::BMWT. Imaging was performed over 50 940 
minutes (1 frame/ 2.5 min). 941 
 942 
Supplemental Table 1:  Details of gene expression analysis. Seurat based differential 943 
analysis (non-parameteric Wilcoxon rank sum test) was performed by comparing cell 944 
types amongst each other (green columns) and the different Seurat clusters (yellow 945 
columns). p_val: p_val (unadjusted). avg_logFC: log fold-change of the average 946 
expression between the two groups. Positive values indicate that the feature is more 947 
highly expressed in the first group. pct.1: The percentage of cells where the feature is 948 
detected in the first group. pct.2: The percentage of cells where the feature is detected in 949 
the second group. p_val_adj: Adjusted p-value, based on Bonferroni correction using all 950 
features in the dataset. 951 
 952 
Supplemental Table 2:  Marker genes for EC subtypes of multiple tumour types. 953 
p_val: p_val (unadjusted). avg_logFC: Average log (fold change). pct.1: Percentage of 954 
expressed cells in current cluster. pct.2: Percentage of expressed cells in other cluster. 955 
p_val_adj: Adjusted p-value. cluster: Cluster name. gene: Gene name. log2fc: log2 (fold 956 
change). Log2pct: log2 ((pct+0.005)/(pct2+0.005)). 957 
 958 
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Matsumoto K et al., Figure1
Fig. 1: Csf1r lineage endothelial cells (CLECs) contribute to perfused, dynamically sprouting and remodeling blood vessels in 
mouse glioma. a, Csf1r-Mer2.CremTmG: a mouse model for Csf1r-lineage tracing combining the tamoxifen-inducible Cre-driver under control 
of the Csf1r-promoter and the mTmG Cre-reporter. b, Timing schedule of glioma implantation, tamoxifen induction and in vivo imaging. c-f, 
Longitudinal intravital imaging of the tumour vasculature in CT2A mouse glioma of Csf1r-Mer2.CremTmG by cranial window. Scale bar: 50 µm. 
c, In vivo imaging in 3 weeks glioma. Endothelial cells in red (tdTomato), Csf1r-labeled cells in green (GFP) and glioma cells in blue (BFP). d, 
Detail image of outlined square in Fig. 1c illustrating tracing of GFP-positive cells. White arrowheads, macrophages; blue arrowhead, CLECs 
at tip position. e, In vivo imaging of CLECs in 2 weeks glioma. Blue arrowheads, tip of endothelial cells. f, Visualization of blood vessels in 3 
weeks glioma by Intravenous injection of dextran with texas red dye. Yellow arrowhead, bridging CLECs; orange arrowhead, tube formation 
by CLECs; blue arrowhead, CLECs at tip position. g-h, Counterstaining on PFA-fixed 4 weeks CT2A glioma sections of Csf1r-Mer2.CremTmG 
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Matsumoto K et al., Figure 2
Fig. 2: Up to 10% of intra-tumour endothelium is comprised of CLECs not only in glioma, but also in other tumour types and 
locations. a-f, Quantification of the population of CLECs in glioma of Csf1r-Mer2.CremTmG mice. a, Gross appearance of sham control 
and 4 weeks CT2A glioma (Upper panel). Purple arrowhead, the area of capillary injection; blue arrowhead, glioma. Scale bar: 5 mm. 
Flow cytometric analysis of CLECs in sham control and 4 weeks CT2A glioma (Lower panel). b, In 3 weeks CT2A glioma (n= 9), 
CLECs constitute 2.1 ± 1.0% of total endothelial cells (CD45-CD31+); in 4 weeks CT2A glioma (n= 5), they make up 7.5 ± 1.6% of total 
endothelial cells. c, In 3 weeks GL261 glioma (n= 5), CLECs constitute 1.5 ± 1.6% of total endothelial cells. d, Gross appearance of 
normal brain, sham control and 3 weeks CT2A glioma. Purple arrowhead, area of capillary injection. Scale bar: 5 mm. e-f, 
Quantification of the population of CLECs by flow cytometric analysis in brain and tumour samples. Bars represent mean ± s.d. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Two-tailed unpaired Mann-Whitney’ s U test. g-h, Analysis of CLECs in B16F1 
melanoma in Csf1r-Mer2.CremTmG mice. g, Counterstaining on PFA-fixed section of day12 melanoma with CDH5 antibody. Yellow 
arrows, CLECs. Scale bar: 50 µm. h, CLECs constitute 2.8 ± 0.75% of total endothelial cells in day 12 melanoma (n=4).
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Matsumoto K et al., Figure 3
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Fig. 3: CLECs do not originate from bone marrow.  a-b, Flow cytometric analysis of CT2A-glioma in bone marrow chimeras.
 a, BMCsf1r-mer2.CremTmG: C57BL/6J mice are used as recipients and  Csf1r-Mer2.CremTmG mice used as donors. Within the sorted myeloid cell 
population (BFP-CD45+), 32.3 ± 12.1% are GFP-positive in Csf1r-Mer2.CremTmG mice (n= 10), and 33.8 ± 6.9% are GFP-positive in bone-marrow 
transplanted BMCsf1r-Mer2.CremTmG mice (n= 12). Among endothelial cell population (BFP-CD45-CD31+), 4.3 ± 1.9% are GFP-positive in 
Csf1r-Mer2.CremTmG mice (n= 10), whereas no GFP-positive endothelial cells are found in BMCsf1r-Mer2.CremTmG mice (n= 12). b, Csf1r-Mer2.CremTmG:: 
BMWT: Csf1r-Mer2.CremTmG are used as recipients and C57BL/6J as donors. Of the sorted myeloid cell population, 43.4 ± 11.3% GFP-positive cells 
are found in Csf1r-Mer2.CremTmG mice (n= 6), whereas 0.1 ± 0.1% GFP-positive cells are found in Csf1r-Mer2.CremTmG:: BMWT mice (n= 4). Of the 
endothelial cell population, 10.5 ± 9.7% GFP-positive cells are found in Csf1r-Mer2.CremTmG mice (n= 6), and 9.3 ± 3.7% GFP-positive cells are 
found in Csf1r-Mer2.CremTmG:: BMWT mice (n= 4). Bars represent mean ± s.d. *P<0.05,**P<0.01,***P<0.001, ****P<0.0001. Two-tailed unpaired 
Mann-Whitney’ s U test.  c, Longitudinal intravial imaging of 2 weeks CT2A glioma of Csf1r-Mer2.CremTmG and Csf1r-Mer2.CremTmG :: BMWT mice. 
White arrows, CLECs. Scale bar: 50 µm.  
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Fig. 4: Dual recombination lineage tracing and inducible depletion model identifies a role for CLECs in tumour blood vessel 
patterning supporting glioma growth. a, Cdh5-Dre: Csf1r-Mer2.Cre: RSR-LSL-tdTomato (DreMer2.CretdTomato): a genetic mouse model for 
CLEC selective tracing by dual recombination. b-c, Analysis in DreMer2.CretdTomato. b, Longitudinal intravital imaging of the tumour 
vasculature in 3 weeks CT2A mouse glioma by Intravenous injection of  FITC dextran. Yellow arrowheads, CLECs. Scale bar: 50 µm. c, 
ERG antibody counterstaining on PFA-fixed sections of 3 weeks CT2A glioma. Yellow arrows, CLECs. Scale bar: 50 µm. d, Cdh5-Dre: 
Csf1r-Mer2.Cre: RSR-mTmG-DTR (DreMer2.CremTmG-DTR): a genetic mouse model for CLEC selective tracing and inducible ablation.  DTR, 
diphtheria toxin receptor. e-l, Analysis in DreMer2.CremTmG-DTR. e, Longitudinal intravital imaging of the tumour vasculature in 3 weeks CT2A 
mouse glioma. Mer2.CremTmG, Csf1r-Mer2.CremTmG. Yellow arrowheads, CLECs. f, Timing schedule of glioma implantation, tamoxifen 
induction and diphtheria toxin (DT) treatment. g, Gross appearance of 3 weeks CT2A gliomas. Scale bar: 5 mm. h, Confocal images of 
PFA-fixed 3 weeks CT2A glioma sections. Yellow arrows, CLECs. Scale bar: 50 µm. i, Tumour weight at 3 weeks CT2A glioma. j-l, Analysis 
of PFA-fixed 3 weeks CT2A glioma sections. j, Tumour blood vessels area. k, Network length of tumour blood vessels. l, Number of 
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Matsumoto K et al., Figure 5
Fig. 5: Single-cell analysis identifies a unique signature that defines the tumour CLECs. a-d, Single-cell RNA sequencing 
(scRNA-seq) analysis of tumour macrophages (T_MACs: CD45+GFP+, 79 cells), tumour endothelial cell (T_ECs: CD45-CD31+GFP-, 78 
cells), tumour CLECs (T_CLECs: CD45-CD31+GFP+, 141 cells) in 4 weeks CT2A glioma of Csf1r-Mer2.CremTmG mice. b, Gene 
expression of typical endothelial cell markers, macrophages and myeloid cell markers. c, Csf1r gene expression. d, Three  characteristic 
genes expressed in T_CLECs. e, Enrichment of Tip-cell and lymphatic signature in T_CLECs compared to T_ECs as shown by GSEA. 
f-k, Analysis of scRNA-seq data of human endothelial cells from multiple primary tumours. f, UMAP plot of human endothelial cell 
subtypes. g, UMAP plot of human endothelial cells colour-coded for the tumour type of origins. h, UMAP plots with marker gene 
expression for each EC subtype. i, Heatmap of marker gene expression for each EC phenotype (each cell as a column and each gene 
as a row).  j-k, AUCell analysis of 24 T_CLECs markers. j, T_CLECs subpopulation indicated (AUC>0.165) by red colored dots. k, Cell 
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Fig. 6: CLECs are linked to Prox1-positive lymphatic endothelium of the subcapsular sinus floor in lymph nodes. a, Fluorescent images of the 
indicated organs of Csf1r-Mer2.CremTmG mice after multiple tamoxifen induction. Scale bar: 50 µm. b, Quantification of the population of CLECs in 
Csf1r-Mer2.CremTmG mice by flow cytmetric analysis. Of the endothelial cell population (CD45-CD31+), 9.8 ± 2.1% GFP-positive cells are found in the 
axillary lymph node of Csf1r-Mer2.CremTmG mice (n= 10). c, Counterstaining on PFA-fixed Inguinal lymph node of Csf1r-Mer2.CremTmG:: BMWT mice 
using PROX1 antibody within 24 hours after tamoxifen induction. Yellow arrowheads, GFP+tdTomato+PROX1+ cells in the floor of the subcapsular 
sinus. Scale bar 25 µm. d, Fluorescent images of PROX1 antibody counterstaining on PFA-fixed inguinal lymph node of Csf1r-Mer2.CremTmG::BMWT 
mice after multiple rounds of tamoxifen induction. Scale bar: 100 µm.  Detailed image of square outlined in d. Yellow arrowheads, GFP+Prox1+ cells; 
blue arrowheads, GFP+Prox1- cells.  
Matsumoto K et al., Figure 6
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Fig. 7: CLEC and EC heterogeneity in tumor and lymph node .
 a, Quality measures of 4 SMARTseq2 scRNA-seq. libraries: Csf1r-lineage endothelial cells (CLECs) and endothelial cells (ECs) isolated from tumor 
(T_) and lymph node (LN_). b, Violin plots show GFP expression per single cell. c, Uniform manifold approximation and projection (UMAP) of 
T_CLECs, T_ECs and LN_CLECs, LN_ECs. d, Heatmap shows the 20 most characteristic markers per cell population. e, UMAP colored by gene 
expression diversity (CytoTRACE score) and predicted ordering by CytoTRACE. f, Monocle based trajectory analysis of four cell populations, colored 
by pseudotime and CytoTRACE score.
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